{"version":"1.0","type":"link","title":"Letter to the Editor - Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer an exploratory, open-label phase II study.","author_name":"Sun M 외","author_url":"https://prs-insight.online/author/Sun%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/87428","thumbnail_width":1200,"thumbnail_height":630}